In his new role, Shisher will lead Glenmark’s marketing initiatives, focusing on strengthening brand positioning, driving market expansion, and accelerating growth
The product is bioequivalent and therapeutically equivalent to the reference listed drug by Fresenius Kabi USA, LLC.
This marks a meaningful step in the company's continued expansion in the region
Glenmark's Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg is the authorized generic to Savella Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg
The product is bioequivalent and therapeutically equivalent to Fresenius Kabi’s reference drug (NDA 212832)
The product addresses a market with approximately $66.8 million in annual sales as of December 2025.
According to IQVIA sales data for the 12-month period ending October 2025, the Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) market2 achieved annual sales of approximately $67.6 million
Glenmark's Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug
The positive outcome clears the way for Glenmark to resume commercial manufacturing at the site
Glenmark will begin distribution in November 2025
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
